Evidence map›Paper›PMID 33436392›Full record

ArticleCold Spring Harbor molecular case studies2021

Refractory alveolar rhabdomyosarcoma in an 11-year-old male.

Cora A Ricker, Andrew D Woods, William Simonson, Melvin Lathara, Ganapati Srinivasa, Erin R Rudzinski, Atiya Mansoor, Robert G Irwin, Charles Keller, Noah E Berlow

Open access · diamondAbstract read
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Cora A RickerChildren's Cancer Therapy Development Institute, Beaverton, Oregon 97005, USA.
Andrew D WoodsChildren's Cancer Therapy Development Institute, Beaverton, Oregon 97005, USA.
William SimonsonMary Bridge Hospital, Tacoma, Washington 98403, USA.
Melvin LatharaOmics Data Automation, Beaverton, Oregon 97005, USA.
Ganapati SrinivasaOmics Data Automation, Beaverton, Oregon 97005, USA.
Erin R RudzinskiDepartment of Laboratories, Seattle Children's Hospital, Seattle, Washington 98105, USA.
Atiya MansoorChildren's Cancer Therapy Development Institute, Beaverton, Oregon 97005, USA.
Robert G IrwinMary Bridge Hospital, Tacoma, Washington 98403, USA.
Charles KellerChildren's Cancer Therapy Development Institute, Beaverton, Oregon 97005, USA.ORCID 0000-0003-2505-7487
Noah E BerlowChildren's Cancer Therapy Development Institute, Beaverton, Oregon 97005, USA.
Children's Cancer Therapy Development Institute · USAutomatic Data Processing (United States) · USMary Bridge Children's Health Center · USSeattle Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rhabdomyosarcoma (RMS) is a mesenchymal malignancy phenocopying muscle and is among the leading causes of death from childhood cancer. Metastatic alveolar rhabdomyosarcoma is the most aggressive subtype with an 8% 5-yr disease-free survival rate when a chromosomal fusion is present and a 29% 5-yr disease-free survival rate when negative for a fusion event. The underlying biology of

Indexed as

Antineoplastic AgentsChildDrug Screening Assays, AntitumorExome SequencingGerm CellsHumansMaleRhabdomyosarcoma, AlveolarTumor Suppressor Protein p53Antineoplastic AgentsTP53 protein, humanTumor Suppressor Protein p53rhabdomyosarcoma

Identifiers

PMID33436392
PMCPMC7903883
OpenAlexW3120772093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.